![]()
Gene-Chemical Interaction Annotations Click to see Annotation Detail View
Term | Qualifier | Evidence | With | Reference | Notes | Source | Original Reference(s) | (-)-epigallocatechin 3-gallate | multiple interactions | ISO | RGD:1601904 | 6480464 | [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of HACD4 mRNA | CTD | PMID:22079256 | 1,2-dichloroethane | decreases expression | ISO | RGD:1321187 | 6480464 | ethylene dichloride results in decreased expression of HACD4 mRNA | CTD | PMID:28960355 | 1-naphthyl isothiocyanate | increases expression | EXP | | 6480464 | 1-Naphthylisothiocyanate results in increased expression of HACD4 mRNA | CTD | PMID:30723492 | 17beta-estradiol | increases expression | ISO | RGD:1321187 | 6480464 | Estradiol results in increased expression of HACD4 mRNA | CTD | PMID:19484750 | 17beta-estradiol | multiple interactions | ISO | RGD:1601904 | 6480464 | [Estradiol co-treated with Progesterone] results in increased expression of HACD4 mRNA | CTD | PMID:20660070 | 2,2',4,4'-Tetrabromodiphenyl ether | decreases expression | EXP | | 6480464 | 2 more ... | CTD | PMID:27291303 | 2,3,7,8-tetrachlorodibenzodioxine | multiple interactions | ISO | RGD:1321187 | 6480464 | Tetrachlorodibenzodioxin promotes the reaction [AHR protein binds to HACD4 promoter] | CTD | PMID:19654925 | 2,3,7,8-tetrachlorodibenzodioxine | decreases expression | EXP | | 6480464 | Tetrachlorodibenzodioxin results in decreased expression of HACD4 mRNA | CTD | PMID:33387578 | 2,3,7,8-tetrachlorodibenzodioxine | affects expression | ISO | RGD:1321187 | 6480464 | Tetrachlorodibenzodioxin affects the expression of HACD4 mRNA | CTD | PMID:21570461 | 2,3,7,8-Tetrachlorodibenzofuran | increases expression | EXP | | 6480464 | 2 more ... | CTD | PMID:32109520 | 3-chloropropane-1,2-diol | decreases expression | EXP | | 6480464 | alpha-Chlorohydrin results in decreased expression of HACD4 mRNA | CTD | PMID:28522335 | 3-isobutyl-1-methyl-7H-xanthine | multiple interactions | ISO | RGD:1601904 | 6480464 | [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of HACD4 mRNA | CTD | PMID:28628672 | 3-methylcholanthrene | increases expression | ISO | RGD:1321187 | 6480464 | Methylcholanthrene results in increased expression of HACD4 mRNA | CTD | PMID:20713471 | 4,4'-sulfonyldiphenol | increases expression | ISO | RGD:1321187 | 6480464 | bis(4-hydroxyphenyl)sulfone results in increased expression of HACD4 mRNA | CTD | PMID:30951980 | 4-hydroxyphenyl retinamide | increases expression | ISO | RGD:1321187 | 6480464 | Fenretinide results in increased expression of HACD4 mRNA | CTD | PMID:28973697 | 4-hydroxyphenyl retinamide | decreases expression | ISO | RGD:1321187 | 6480464 | Fenretinide results in decreased expression of HACD4 mRNA | CTD | PMID:28973697 | 6-propyl-2-thiouracil | decreases expression | EXP | | 6480464 | Propylthiouracil results in decreased expression of HACD4 mRNA | CTD | PMID:24780913, PMID:25825206 | acetamide | increases expression | EXP | | 6480464 | acetamide results in increased expression of HACD4 mRNA | CTD | PMID:31881176 | acrylamide | decreases expression | EXP | | 6480464 | Acrylamide results in decreased expression of HACD4 mRNA | CTD | PMID:28959563 | all-trans-retinoic acid | increases expression | ISO | RGD:1601904 | 6480464 | Tretinoin results in increased expression of HACD4 mRNA | CTD | PMID:33167477 | aristolochic acid A | increases expression | ISO | RGD:1601904 | 6480464 | aristolochic acid I results in increased expression of HACD4 mRNA | CTD | PMID:33212167 | arsenite(3-) | increases expression | ISO | RGD:1321187 | 6480464 | arsenite results in increased expression of HACD4 mRNA | CTD | PMID:18929588 | arsenite(3-) | decreases expression | ISO | RGD:1601904 | 6480464 | arsenite results in decreased expression of HACD4 mRNA | CTD | PMID:23974009 | arsenite(3-) | multiple interactions | ISO | RGD:1321187 | 6480464 | TRP53 protein affects the reaction [arsenite results in increased expression of HACD4 mRNA] | CTD | PMID:18929588 | arsenous acid | increases expression | ISO | RGD:1601904 | 6480464 | Arsenic Trioxide results in increased expression of HACD4 mRNA | CTD | PMID:26705709 | atrazine | decreases expression | ISO | RGD:1601904 | 6480464 | Atrazine results in decreased expression of HACD4 mRNA | CTD | PMID:22378314 | benzo[a]pyrene | multiple interactions | ISO | RGD:1321187 | 6480464 | Benzo(a)pyrene promotes the reaction [AHR protein binds to HACD4 promoter] | CTD | PMID:19654925 | benzo[a]pyrene | increases expression | ISO | RGD:1321187 | 6480464 | Benzo(a)pyrene results in increased expression of HACD4 mRNA | CTD | PMID:22228805 | bilirubin IXalpha | decreases expression | ISO | RGD:1601904 | 6480464 | Bilirubin results in decreased expression of HACD4 mRNA | CTD | PMID:20196124 | bisphenol A | decreases expression | EXP | | 6480464 | bisphenol A results in decreased expression of HACD4 mRNA | CTD | PMID:25181051 more ... | bisphenol A | increases expression | EXP | | 6480464 | bisphenol A results in increased expression of HACD4 mRNA | CTD | PMID:34947998 | bisphenol A | increases expression | ISO | RGD:1601904 | 6480464 | bisphenol A results in increased expression of HACD4 mRNA | CTD | PMID:29275510 | bisphenol A | increases expression | ISO | RGD:1321187 | 6480464 | bisphenol A results in increased expression of HACD4 mRNA | CTD | PMID:30951980, PMID:32156529 | bisphenol A | multiple interactions | ISO | RGD:1601904 | 6480464 | [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of HACD4 mRNA | CTD | PMID:28628672 | bisphenol F | increases expression | ISO | RGD:1321187 | 6480464 | bisphenol F results in increased expression of HACD4 mRNA | CTD | PMID:30951980 | carbon nanotube | decreases expression | ISO | RGD:1321187 | 6480464 | Nanotubes more ... | CTD | PMID:25554681 | CGP 52608 | multiple interactions | ISO | RGD:1601904 | 6480464 | CGP 52608 promotes the reaction [RORA protein binds to HACD4 gene] | CTD | PMID:28238834 | choline | multiple interactions | ISO | RGD:1321187 | 6480464 | [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased expression of HACD4 mRNA | CTD | PMID:20938992 | cisplatin | multiple interactions | ISO | RGD:1321187 | 6480464 | [Cisplatin co-treated with RELB mutant form co-treated with TNF protein] results in decreased expression of HACD4 mRNA | CTD | PMID:23625948 | crocidolite asbestos | decreases expression | ISO | RGD:1601904 | 6480464 | Asbestos, Crocidolite results in decreased expression of HACD4 mRNA | CTD | PMID:29523930 | dexamethasone | multiple interactions | ISO | RGD:1601904 | 6480464 | [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of HACD4 mRNA | CTD | PMID:28628672 | diarsenic trioxide | increases expression | ISO | RGD:1601904 | 6480464 | Arsenic Trioxide results in increased expression of HACD4 mRNA | CTD | PMID:26705709 | dioxygen | multiple interactions | ISO | RGD:1321187 | 6480464 | [NFE2L2 protein affects the susceptibility to Oxygen] which affects the expression of HACD4 mRNA | CTD | PMID:30529165 | dorsomorphin | multiple interactions | ISO | RGD:1601904 | 6480464 | [NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1 more ... | CTD | PMID:27188386 | doxorubicin | decreases expression | ISO | RGD:1601904 | 6480464 | Doxorubicin results in decreased expression of HACD4 mRNA | CTD | PMID:29803840 | endosulfan | increases expression | EXP | | 6480464 | Endosulfan results in increased expression of HACD4 mRNA | CTD | PMID:29391264 | entinostat | increases expression | ISO | RGD:1601904 | 6480464 | entinostat results in increased expression of HACD4 mRNA | CTD | PMID:27188386 | fenamidone | increases expression | ISO | RGD:1321187 | 6480464 | fenamidone results in increased expression of HACD4 mRNA | CTD | PMID:27029645 | fenvalerate | increases expression | EXP | | 6480464 | fenvalerate results in increased expression of HACD4 mRNA | CTD | PMID:30307764 | fluoranthene | multiple interactions | ISO | RGD:1321187 | 6480464 | [1-methylanthracene co-treated with fluoranthene] results in decreased expression of HACD4 mRNA | CTD | PMID:28329830 | folic acid | multiple interactions | ISO | RGD:1321187 | 6480464 | [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased expression of HACD4 mRNA | CTD | PMID:20938992 | gentamycin | decreases expression | EXP | | 6480464 | Gentamicins results in decreased expression of HACD4 mRNA | CTD | PMID:33387578 | hydrogen peroxide | affects expression | ISO | RGD:1601904 | 6480464 | Hydrogen Peroxide affects the expression of HACD4 mRNA | CTD | PMID:21179406 | indometacin | multiple interactions | ISO | RGD:1601904 | 6480464 | [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of HACD4 mRNA | CTD | PMID:28628672 | L-methionine | multiple interactions | ISO | RGD:1321187 | 6480464 | [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased expression of HACD4 mRNA | CTD | PMID:20938992 | lead diacetate | decreases expression | EXP | | 6480464 | lead acetate results in decreased expression of HACD4 mRNA | CTD | PMID:22641619 | methylmercury chloride | decreases expression | ISO | RGD:1601904 | 6480464 | methylmercuric chloride results in decreased expression of HACD4 mRNA | CTD | PMID:28001369 | nickel sulfate | decreases expression | ISO | RGD:1601904 | 6480464 | nickel sulfate results in decreased expression of HACD4 mRNA | CTD | PMID:22714537 | oxaliplatin | multiple interactions | EXP | | 6480464 | [oxaliplatin co-treated with Topotecan] results in increased expression of HACD4 mRNA | CTD | PMID:25729387 | paracetamol | decreases expression | EXP | | 6480464 | Acetaminophen results in decreased expression of HACD4 mRNA | CTD | PMID:33387578 | phenobarbital | multiple interactions | ISO | RGD:1321187 | 6480464 | NR1I3 protein affects the reaction [Phenobarbital results in increased expression of HACD4 mRNA] | CTD | PMID:19482888 | phenobarbital | increases expression | ISO | RGD:1321187 | 6480464 | Phenobarbital results in increased expression of HACD4 mRNA | CTD | PMID:19482888 | phenylmercury acetate | increases expression | ISO | RGD:1601904 | 6480464 | Phenylmercuric Acetate results in increased expression of HACD4 mRNA | CTD | PMID:26272509 | phenylmercury acetate | multiple interactions | ISO | RGD:1601904 | 6480464 | [NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HACD4 mRNA | CTD | PMID:27188386 | pirinixic acid | decreases expression | ISO | RGD:1321187 | 6480464 | pirinixic acid results in decreased expression of HACD4 mRNA | CTD | PMID:23811191 | potassium chromate | decreases expression | ISO | RGD:1601904 | 6480464 | potassium chromate(VI) results in decreased expression of HACD4 mRNA | CTD | PMID:22079256 | potassium chromate | multiple interactions | ISO | RGD:1601904 | 6480464 | [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of HACD4 mRNA | CTD | PMID:22079256 | progesterone | multiple interactions | ISO | RGD:1601904 | 6480464 | [Estradiol co-treated with Progesterone] results in increased expression of HACD4 mRNA | CTD | PMID:20660070 | rotenone | decreases expression | EXP | | 6480464 | Rotenone results in decreased expression of HACD4 mRNA | CTD | PMID:28374803 | SB 431542 | multiple interactions | ISO | RGD:1601904 | 6480464 | [NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1 more ... | CTD | PMID:27188386 | silicon dioxide | decreases expression | ISO | RGD:1601904 | 6480464 | Silicon Dioxide analog results in decreased expression of HACD4 mRNA | CTD | PMID:25895662 | silicon dioxide | decreases expression | ISO | RGD:1321187 | 6480464 | Silicon Dioxide results in decreased expression of HACD4 mRNA | CTD | PMID:19073995 | silver atom | decreases expression | ISO | RGD:1321187 | 6480464 | Silver results in decreased expression of HACD4 mRNA | CTD | PMID:27131904 | silver(0) | decreases expression | ISO | RGD:1321187 | 6480464 | Silver results in decreased expression of HACD4 mRNA | CTD | PMID:27131904 | sodium fluoride | increases expression | ISO | RGD:1321187 | 6480464 | Sodium Fluoride results in increased expression of HACD4 mRNA | CTD | PMID:27862939 | tetrachloroethene | increases expression | ISO | RGD:1321187 | 6480464 | Tetrachloroethylene results in increased expression of HACD4 mRNA | CTD | PMID:28973375 | tetrachloromethane | affects expression | ISO | RGD:1321187 | 6480464 | Carbon Tetrachloride affects the expression of HACD4 mRNA | CTD | PMID:17484886 | tetrachloromethane | increases expression | ISO | RGD:1321187 | 6480464 | Carbon Tetrachloride results in increased expression of HACD4 mRNA | CTD | PMID:27339419 more ... | thioacetamide | decreases expression | EXP | | 6480464 | Thioacetamide results in decreased expression of HACD4 mRNA | CTD | PMID:34492290 | titanium dioxide | decreases expression | ISO | RGD:1321187 | 6480464 | titanium dioxide results in decreased expression of HACD4 mRNA | CTD | PMID:23557971 | topotecan | multiple interactions | EXP | | 6480464 | [oxaliplatin co-treated with Topotecan] results in increased expression of HACD4 mRNA | CTD | PMID:25729387 | trichostatin A | increases expression | ISO | RGD:1601904 | 6480464 | trichostatin A results in increased expression of HACD4 mRNA | CTD | PMID:24935251, PMID:26272509 | trichostatin A | multiple interactions | ISO | RGD:1601904 | 6480464 | [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HACD4 mRNA | CTD | PMID:27188386 | triclosan | decreases expression | ISO | RGD:1601904 | 6480464 | Triclosan results in decreased expression of HACD4 mRNA | CTD | PMID:30510588 | trovafloxacin | decreases expression | ISO | RGD:1321187 | 6480464 | trovafloxacin results in decreased expression of HACD4 mRNA | CTD | PMID:35537566 | valproic acid | increases expression | ISO | RGD:1601904 | 6480464 | Valproic Acid results in increased expression of HACD4 mRNA | CTD | PMID:23179753 more ... | valproic acid | affects expression | ISO | RGD:1601904 | 6480464 | Valproic Acid affects the expression of HACD4 mRNA | CTD | PMID:25979313 | valproic acid | multiple interactions | ISO | RGD:1601904 | 6480464 | [NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HACD4 mRNA | CTD | PMID:27188386 | |